Published in J Clin Oncol on October 01, 2007
Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet (2012) 5.42
High throughput characterization of combinatorial histone codes. Mol Cell Proteomics (2009) 2.52
Global levels of histone modifications predict prognosis in different cancers. Am J Pathol (2009) 2.28
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel) (2013) 1.65
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol (2010) 1.57
Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis. PLoS One (2014) 1.41
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res (2010) 1.21
Replication timing: a fingerprint for cell identity and pluripotency. PLoS Comput Biol (2011) 1.21
Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation. J Biol Chem (2013) 1.17
Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res (2012) 1.15
Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10
Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci (2008) 1.10
γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta (2012) 1.07
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One (2012) 1.06
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med (2009) 1.03
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Vitamin d and susceptibility of chronic lung diseases: role of epigenetics. Front Pharmacol (2011) 1.03
microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med (2011) 1.03
The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. Cancer Cell (2015) 1.02
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
Epigenetics of lung cancer. Transl Res (2014) 0.95
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? World J Biol Chem (2015) 0.94
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One (2010) 0.93
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One (2013) 0.92
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther (2014) 0.91
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. Proteomics (2009) 0.90
Alterations of histone H1 phosphorylation during bladder carcinogenesis. J Proteome Res (2013) 0.90
Imaging the clear cell renal cell carcinoma proteome. J Urol (2012) 0.90
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol (2013) 0.89
Lung cancer: a modified epigenome. Cell Adh Migr (2010) 0.89
Analysis of Histone Modifications from Tryptic Peptides of Deuteroacetylated Isoforms. Int J Mass Spectrom (2012) 0.89
Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets (2013) 0.87
The significance of epigenetic alterations in lung carcinogenesis. Mol Biol Rep (2012) 0.86
The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers (Basel) (2011) 0.86
Common features of chromatin in aging and cancer: cause or coincidence? Trends Cell Biol (2014) 0.86
Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer (2013) 0.86
Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics (2008) 0.85
Oncometabolites: tailoring our genes. FEBS J (2015) 0.85
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Oncotarget (2014) 0.84
Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer. J Proteome Res (2013) 0.83
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget (2016) 0.83
Epigenetics meets radiation biology as a new approach in cancer treatment. Int J Mol Sci (2013) 0.83
Protein Arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders. Int J Mol Sci (2012) 0.82
Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI J (2014) 0.81
Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem (2014) 0.80
Quantitative Mass Spectrometry Reveals that Intact Histone H1 Phosphorylations are Variant Specific and Exhibit Single Molecule Hierarchical Dependence. Mol Cell Proteomics (2015) 0.79
Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma. Invest Ophthalmol Vis Sci (2015) 0.78
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett (2016) 0.78
Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications. Reprod Sci (2013) 0.77
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells. Clin Proteomics (2015) 0.76
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics (2016) 0.75
Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma. PLoS One (2016) 0.75
Epigenetic Modifications and Accumulation of DNA Double-Strand Breaks in Oral Lichen Planus Lesions Presenting Poor Response to Therapy. Medicine (Baltimore) (2015) 0.75
Down-Regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells. J Biol Chem (2017) 0.75
Epigenetics and chromatin remodeling play a role in lung disease. Tanaffos (2011) 0.75
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling. Int J Mol Sci (2016) 0.75
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget (2016) 0.75
Correlation between histone acetylation and expression of Notch1 in human lung carcinoma and its possible role in combined small-cell lung carcinoma. Lab Invest (2017) 0.75
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med (2010) 10.44
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
High level of burnout in intensivists: prevalence and associated factors. Am J Respir Crit Care Med (2007) 3.92
Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44
Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) (2014) 2.37
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med (2005) 1.85
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer (2006) 1.67
Is maternal posturing during labor efficient in preventing persistent occiput posterior position? A randomized controlled trial. Am J Obstet Gynecol (2012) 1.59
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood (2010) 1.56
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med (2012) 1.54
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis (2008) 1.53
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Prognostic impact of the extracapsular lymph node involvement on disease-free survival according to the 7th edition of American Joint Committee on Cancer Staging System. Eur J Cardiothorac Surg (2013) 1.50
Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg (2005) 1.49
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol (2007) 1.48
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol (2010) 1.36
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34
Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci (2014) 1.34
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res (2004) 1.34
TGF-β as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol (2012) 1.33
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer (2006) 1.33
Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg (2007) 1.33
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell (2006) 1.33
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30
Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol (2005) 1.30
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther (2006) 1.28
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res (2012) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol (2013) 1.22
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer (2007) 1.21
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.21
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract (2011) 1.16
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 1.16
Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol (2010) 1.15
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol (2004) 1.13
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.12
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res (2010) 1.12
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther (2007) 1.11